Mental Health IOP – Summary
Summary of Published Mental Health IOP Outcome Research Results
90% of the patients admitted to this IOP suffer from severe depression with co-morbid Axis I diagnoses (49%), usually anxiety. 80% had already been prescribed antidepressants, but these were not enough to return the individual to their baseline level of functioning and additional treatment was warranted. 71% have complicating personality characteristics, 55% have co-existing medical disorders and 70% of those were pain related. 32% had an average of 2 previous psychiatric inpatient admissions, usually for depression.
25% of those with previous inpatient admissions had more than 3 prior admissions prior to coming to our IOP. 74% of our IOP admissions were experiencing suicidal ideation at the time of Intake, but with careful planning, we were able to effectively and safely treat these patients while they remained at home. In our ongoing research, we have proven that this treatment program is effective in treating severe depression for the majority of patients. Our IOP is comprised of evidence based psychological treatments and we have calculated a dose : response relationship between the average length of time in treatment and the average patient rating of depression symptoms in each week. As you can see in the first dose : response graph, this treatment has proven to be very effective for reducing depression.
In fact, you can see the dose : response graph for patients diagnosed with anxiety disorders, in addition to a depressive disorder, in the second graph. These patients started our intensive outpatient program with severe anxiety symptoms that often rise to the level of phobic anxiety. This includes symptoms such as feeling fearful without apparent reason, heart palpitations, episodes of terror or panic, thoughts and images of a frightening nature and avoiding people, places or things because they are reminders of traumatic events.
Diagnostically, these symptoms represent those with generalized anxiety disorder, post traumatic stress disorder, social anxiety disorder and phobic levels of anxiety. Furthermore, our research shows that our typical patient experiences significant more anxiety than both local and national inpatients, but we are able to successfully treat these people in our intensive outpatient program while they live at home. On average, about 75% of patients of these patients who are diagnosed with both depression and an anxiety disorder significantly reduce their anxiety symptoms, in addition to their depression, if they complete our treatment program. We have produced similar results with our intensive outpatient treatment program for individuals suffering from substance abuse, stress and other psychiatric disorders. Only 3-4% of all treated patients were referred to an inpatient psychiatric hospital and these were due to concerns for their safety. Just like other forms of treatment, to receive the best results you must receive the proper dose of treatment for the recommended duration of time.
These findings are very remarkable when you consider that on average, MHR’s IOP patients start treatment with more severe symptoms than both Memphis and nationally hospitalized patients. Also, 79% of MHR’s depressed patients who complete treatment improve, and up to 90% of these started treatment feeling suicidal. Similar outcomes have been demonstrated for anxiety, general psychiatric distress and other psychiatric disorders as well. Only 3-4% of all treated patients were referred to any higher level of care and these were due to concerns for their safety .
As you can see in the Table to the left, our consumers consistently report extremely high overall patient satisfaction ratings, averaging 3.7 on a scale of 1 to 4, where 1 = very unsatisfied and 4 = very satisfied. Our clients strongly recommend our program, based on the quality of service and helpfulness of treatment.
Our dual diagnosis treatment outcome and treatment satisfaction study was recently included in an international systematic review of client satisfaction in dual diagnosis treatment programs. This independent, international review found that our overall treatment satisfaction was among the highest in the world.
*Humana is In-Network Insurance for IOP Only